Dataset Information

Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial.

ABSTRACT:

Aims

To evaluate the safety and pharmacokinetics of naringenin in healthy adults consuming whole-orange (Citrus sinensis) extract.

Methods and methods

In a single-ascending-dose randomized crossover trial, 18 adults ingested doses of 150?mg (NAR150), 300?mg (NAR300), 600?mg (NAR600) and 900?mg (NAR900) naringenin or placebo. Each dose or placebo was followed by a wash-out period of at least 1?week. Blood safety markers were evaluated pre-dose and 24?hours post-dose. Adverse events (AEs) were recorded. Serum naringenin concentrations were measured before and over 24?hours following ingestion of placebo, NAR150 and NAR600. Four- and 24-hour serum measurements were obtained after placebo, NAR300 and NAR900 ingestion. Data were analysed using a mixed-effects linear model.

Results

There were no relevant AEs or changes in blood safety markers following ingestion of any of the naringenin doses. The pharmacokinetic variables were: maximal concentration: 15.76?±?7.88??M (NAR150) and 48.45?±?7.88??M (NAR600); time to peak: 3.17?±?0.74?hours (NAR150) and 2.41?±?0.74?hours (NAR600); area under the 24-hour concentration-time curve: 67.61?±?24.36??M?×?h (NAR150) and 199.05?±?24.36??M?×?h (NAR600); and apparent oral clearance: 10.21?±?2.34?L/h (NAR150) and 13.70?±?2.34?L/h (NAR600). Naringenin half-life was 3.0 hours (NAR150) and 2.65?hours (NAR600). After NAR300 ingestion, serum concentrations were 10.67?±?5.74??M (4 hours) and 0.35?±?0.30??M (24?hours). After NAR900 ingestion, serum concentrations were 43.11?±?5.26??M (4 hours) and 0.24?±?0.30??M (24?hours).

Conclusions

Ingestion of 150 to 900?mg doses of naringenin is safe in healthy adults, and serum concentrations are proportional to the dose administered. Since naringenin (8 ?M) is effective in primary human adipocytes, ingestion of 300?mg naringenin twice/d will likely elicit a physiological effect.

SUBMITTER: Rebello CJ

PROVIDER: S-EPMC6956701 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial.

Rebello Candida J CJ Beyl Robbie A RA Lertora Juan J L JJL Greenway Frank L FL Ravussin Eric E Ribnicky David M DM Poulev Alexander A Kennedy Brandon J BJ Castro Hector F HF Campagna Shawn R SR Coulter Ann A AA Redman Leanne M LM

Diabetes, obesity & metabolism 20190930 1

<h4>Aims</h4>To evaluate the safety and pharmacokinetics of naringenin in healthy adults consuming whole-orange (Citrus sinensis) extract.<h4>Methods and methods</h4>In a single-ascending-dose randomized crossover trial, 18 adults ingested doses of 150 mg (NAR150), 300 mg (NAR300), 600 mg (NAR600) and 900 mg (NAR900) naringenin or placebo. Each dose or placebo was followed by a wash-out period of at least 1 week. Blood safety markers were evaluated pre-dose and 24 hours post-dose. Adverse events ...[more]

PMID: 31468636

Similar Datasets

Project description:IntroductionAllopregnanolone is an endogenous neurosteroid with the potential to be a novel regenerative therapeutic for Alzheimer's disease (AD). Foundations of mechanistic understanding and well-established preclinical safety efficacy make it a viable candidate.MethodsA randomized, double-blinded, placebo-controlled, single and multiple ascending dose trial was conducted. Intravenous allopregnanolone or placebo was administered once-per-week for 12 weeks with a 1-month follow-up. Participants with early AD (mild cognitive impairment due to AD or mild AD), a Mini-Mental State Examination score of 20-26 inclusive, and age ≥55 years were randomized (6:2 to three allopregnanolone dosing cohorts or one placebo cohort). Primary endpoint was safety and tolerability. Secondary endpoints included pharmacokinetic (PK) parameters and maximally tolerated dose (MTD). Exploratory endpoints included cognitive and imaging biomarkers.ResultsA total of 24 participants completed the trial. Allopregnanolone was safe and well tolerated in all study participants. No differences were observed between treatment arms in the occurrence and severity of adverse events (AE). Most common AE were mild to moderate in severity and included rash (n = 4 [22%]) and fatigue (n = 3 [17%]). A single non-serious AE, dizziness, was attributable to treatment. There was one serious AE not related to treatment. Pharmacokinetics indicated a predictable linear dose-response in plasma concentration of allopregnanolone after intravenous administration over 30 minutes. The maximum plasma concentrations for the 2 mg, 4 mg, 6 mg, and 10 mg dosages were 14.53 ng/mL (+/-7.31), 42.05 ng/mL (+/-14.55), 60.07 ng/mL (+/-12.8), and 137.48 ng/mL (+/-38.69), respectively. The MTD was established based on evidence of allopregnanolone-induced mild sedation at the highest doses; a sex difference in the threshold for sedation was observed (males 10 mg; females 14 mg). No adverse outcomes on cognition or magnetic resonance imaging-based imaging outcomes were evident.ConclusionsAllopregnanolone was well tolerated and safe across all doses in persons with early AD. Safety, MTD, and PK profiles support advancement of allopregnanolone as a regenerative therapeutic for AD to a phase 2 efficacy trial.Trial registrationClinicalTrials.gov-NCT02221622.

Project description:IntroductionThis randomized, double-blind, placebo-controlled study in healthy volunteers assessed the safety, tolerability, and pharmacokinetics of single ascending doses of intravenously administered NX210-a linear peptide derived from subcommissural organ-spondin-and explored the effects on blood/urine biomarkers and cerebral activity.MethodsParticipants in five cohorts (n = 8 each) were randomized to receive a single intravenous dose of NX210 (n = 6 each) (0.4, 1.25, 2.5, 5, and 10 mg/kg) or placebo (n = 2 each); in total, 10 and 29 participants received placebo and NX210, respectively. Blood samples were collected for pharmacokinetics within 180 min post dosing. Plasma and urine were collected from participants (cohorts: 2.5, 5, and 10 mg/kg) for biomarker analysis and electroencephalography (EEG) recordings within 48 h post dosing. Safety/tolerability and pharmacokinetic data were assessed before ascending to the next dose.ResultsThe study included 39 participants. All dosages were safe and well tolerated. All treatment-emergent adverse events (n = 17) were of mild severity and resolved spontaneously (except one with unknown outcome). Twelve treatment-emergent adverse events (70.6%) were deemed drug related; seven of those (58.3%) concerned nervous system disorders (dizziness, headache, and somnolence). The pharmacokinetic analysis indicated a short half-life in plasma (6-20 min), high apparent volume of distribution (1870-4120 L), and rapid clearance (7440-16,400 L/h). In plasma, tryptophan and homocysteine showed dose-related increase and decrease, respectively. No drug dose effect was found for the glutamate or glutamine plasma biomarkers. Nevertheless, decreased blood glutamate and increased glutamine were observed in participants treated with NX210 versus placebo. EEG showed a statistically significant decrease in beta and gamma bands and a dose-dependent increasing trend in alpha bands. Pharmacodynamics effects were sustained for several hours (plasma) or 48 h (urine and EEG).ConclusionNX210 is safe and well tolerated and may exert beneficial effects on the central nervous system, particularly in terms of cognitive processing.

Dataset Information

Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial.

Aims

Methods and methods

Results

Conclusions

Publications

Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets